 FORT COLLINS, Colo., July 29, 2021 PRNewswire -- Cytocom, Inc., NASDAQ: CBLI, a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured agreements for 90 million in committed capital. 